MENLO PARK, Calif., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, today announced the company will be participating in the...

OPTIC Phase 1 clinical trial initiation expected in 4Q18 Patients to receive a single administration of ADVM-022 delivered intravitreally 6 top U.S. retinal centers participating in the new OPTIC trial MENLO PARK, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Adverum...

- ADVM-053 is a novel gene therapy candidate designed as a potential single‑administration treatment for hereditary angioedema (“HAE”)- Plans to submit an Investigational New Drug (IND) application to the FDA for ADVM-053 in 4Q18 MENLO PARK, Caif. , Aug. 24, 2018...

MENLO PARK, Calif., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, today reported financial results for the second quarter ended...

Dosed First Patient in Cohort 3 in the ADVANCE Phase 1/2 Trial of ADVM-043 Submitted Investigational New Drug (IND) Application for ADVM-022 Plans to submit an IND Application to the FDA for ADVM-053 in 4Q18 MENLO PARK, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) --...

MENLO PARK, Calif., July 24, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced today the appointment of Katherine Bock as vice...

MENLO PARK, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced today that Leone Patterson, interim president and...

-- Single Intravitreal Administration of Gene Therapy ADVM-022 ProvidesLong-term Protection in Nonhuman Primate Model of Wet AMD -- MENLO PARK, Calif., May 17, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company...

MENLO PARK, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, today reported financial results for the first quarter ended...

MENLO PARK, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced that the board of directors and Amber Salzman, Ph.D.,...